Follow-up research from the Pediatric Study of Hepatitis C (PEDS-C) trial reveals that children treated with peginterferon alpha (pegIFN?) for hepatitis C (HCV) display significant changes in height, weight, body mass index (BMI), and body composition. Results appearing in the August issue of Hepatology, a journal of the American Association for the Study of Liver Diseases, indicate that most growth-related side effects are reversible with cessation of therapy. However, in many children the height-for-age score had not returned to baseline two years after stopping treatment. In the U.S...
Realtime Related Tweets
gary carter died cmas cmas tcu dr. oz heart attack grill las vegas the heart attack grill
No comments:
Post a Comment